Option Care Health, Inc. (NASDAQ:OPCH) Shares Bought by Bridges Investment Management Inc.

Bridges Investment Management Inc. raised its position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 133.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,031 shares of the company's stock after purchasing an additional 28,019 shares during the quarter. Bridges Investment Management Inc.'s holdings in Option Care Health were worth $1,714,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Murphy & Mullick Capital Management Corp purchased a new position in shares of Option Care Health during the 4th quarter worth approximately $26,000. Signaturefd LLC boosted its position in shares of Option Care Health by 487.9% during the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company's stock worth $28,000 after buying an additional 1,005 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock worth $40,000 after buying an additional 1,099 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of Option Care Health by 21.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after buying an additional 332 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Option Care Health in the 4th quarter valued at $47,000. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Barrington Research restated an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a report on Wednesday, April 30th. UBS Group raised shares of Option Care Health from a "neutral" rating to a "buy" rating and raised their price objective for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $36.00 target price on shares of Option Care Health in a research note on Wednesday, June 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.50.

Option Care Health Price Performance

Option Care Health stock opened at $30.64 on Thursday. The stock has a market cap of $5.02 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 1.86 and a beta of 0.73. The company has a fifty day simple moving average of $31.90 and a 200-day simple moving average of $31.26. Option Care Health, Inc. has a 12-month low of $21.39 and a 12-month high of $35.53. The company has a current ratio of 1.54, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. The business had revenue of $1.33 billion during the quarter, compared to analysts' expectations of $1.26 billion. Option Care Health had a net margin of 4.12% and a return on equity of 16.90%. The company's revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.26 EPS. Equities analysts expect that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.